Tinzaparin sodium 3,500units in 0.35 ml and 4,500units in 0.45 ml pre-filled syringes will be unavailable between middle of October 2021 and January 2022 (date TBC).
All other presentations of tinzaparin remain unaffected by this supply disruption.
Organisations who use tinzaparin for both prophylaxis and treatment of venous thromboembolism will need to consider if they wish to switch to an alternative low molecular weight heparin (LMWH) for all indications or just for prophylaxis.
This alert contains further information and action for providers.
Please note that no response is required via the CAS website to this alert.